Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

A Unified Naloxone-Guideline Graph

By Jason Hack, MD | on July 26, 2019 | 0 Comment
Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

This graph is an easy-to-understand guideline to help determine if a patient’s clinical status is likely to improve with naloxone administration.

You Might Also Like
  • Naloxone to Reduce Opiate Overdose Deaths Raises Cost, Liability, and Safety Concerns
  • Naloxone Distribution to Patients in Emergency Department Raises Controversy
  • 5 Important Considerations for EMS Naloxone Administration
Explore This Issue
ACEP Now: Vol 38 – No 07 – July 2019

How to Use the Graph

Assess patient’s level of consciousness, respiratory rate, pupil size, and oxygen saturation. Plot those four assessments on the graph. Naloxone administration should be strongly considered in patients who fall into the highlighted quadrant.

Notes: Some patients may not show all of the signs of opioid toxicity. Some opioids do not cause pinpoint pupils (eg, meperidine and propoxyphene). Visit ACEPNow.com for a list of resources for further reading about opioid overdose management.

Naloxone Dosing

A Unified Naloxone-Guideline GraphOpioid-naive patients: 0.4 mg IV should reverse or improve respiratory depression. This dose may be repeated and sequentially increased up to a 10 mg dose.

Opioid-dependent patients: 0.04–0.1 mg IV should reverse or improve respiratory depression without inducing severe precipitated opioid withdrawal. This dose may be repeated and sequentially increased up to a 10 mg dose.

If reversal of respiratory depression does not occur at a naloxone dose of 10 mg IV push, the diagnosis of opioid intoxication must be reconsidered.

Naloxone Facts

  • Naloxone binds to all three recognized opioid receptors (delta, kappa, and mu), with a particularly high affinity for the mu receptor. This causes a competitive antagonism and displacement of opioids, primarily in the central nervous system.
  • Naloxone causes a reversal of the opioid-induced toxic effects, with a primary goal of improving ventilation by reversing respiratory depression and obtundation.
  • Although naloxone is synthesized from thebaine (paramorphine), a natural compound obtained from the opium poppy plant, it has no opioid effects.
  • Naloxone has no intrinsic toxicity in opioid-naive patients even at high doses. It is safe for use in children and adults.
  • Naloxone is well-absorbed by most parenteral routes, most commonly intravenous, intramuscular, subcutaneous, and intranasal.
  • Onset of action depends on route of administration and rate of absorption, ranging from one to six minutes.
  • Naloxone’s duration of effect is 20 to 90 minutes, depending upon the route of administration.
  • Continuous infusion of naloxone, at two-thirds the bolus dose that resulted in arousal, may be required in patients with repeated episodes of respiratory depression or re-sedation.
Resources for Further Reading

  • Boyer EW. Management of opioid analgesic overdose. New Eng J Med. 2012;367(2):146-155.
  • Dowling J, Isbister GK, Kirkpatrick CM, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30(4):490-496.
  • Evans JM, Hogg MI, Lunn JN, et al. Degree and duration of reversal by naloxone of effects of morphine conscious subjects. Br Med J. 1974;2(5919):589-591.
  • Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med. 1991;20(3):246-252.
  • Kerr D, Dietze P, Kelly AM. Intranasal naloxone for the treatment of suspected heroin overdose. Addiction. 2008;103(3):379-386.
  • Naloxone hydrochloride–drug summary. Physicians’ Desk Reference website. Available at: https://www.pdr.net/drug-summary/Naloxone-Hydrochloride-Injection–0-4-mg-mL–naloxone-hydrochloride-777. Accessed May 15, 2019.
  • Nelson LS, Howland MA. Opioid antagonists. In: Nelson LS, Howland MA, Lewin NA, et al, eds. Goldfrank’s Toxicological Emergencies. 11th ed. New York: McGraw-Hill; 2019:538-544.
  • Wanger K, Brough L, Macmillan I, et al. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998;5(4):293-299.

Pages: 1 2 | Single Page

Topics: GuidelinesNaloxoneOpioid CrisisPain and Palliative Care

Related

  • ACEP Clinical Policy on Thrombolytics for Management of Acute Ischemic Stroke

    July 3, 2025 - 0 Comment
  • ACEP Clinical Policy on Outpatient Mgmt. of Adults with Asymptomatic Elevated Blood Pressure

    June 25, 2025 - 0 Comment
  • Prehospital Buprenorphine Is a Powerful Tool in the Opioid-Crisis Fight

    June 4, 2025 - 0 Comment

Current Issue

ACEP Now: July 2025

Download PDF

Read More

About the Author

Jason Hack, MD

Dr. Hack (Oleander Photography) is chief of the division of medical toxicology and vice chair for research at East Carolina University in Greenville, North Carolina. He enjoys taking photographs of beautiful toxic, medicinal, and benign flowers that he stumbles upon or grows in his garden. Contact him at ToxInRI@gmail.com, www.toxinRI.com, or on Instagram @oleanderphotography.

View this author's posts »

No Responses to “A Unified Naloxone-Guideline Graph”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603